Tesamorelin (Egrifta)
Tesamorelin Acetate
The only FDA-approved growth hormone releasing hormone analog specifically for reducing excess abdominal fat in HIV-associated lipodystrophy.
Typical Cost
$600-1200/month
Status
Research
Peptide Profile
Tesamorelin (Egrifta)
Mechanism of Action
Stimulates endogenous growth hormone release with high specificity for visceral fat reduction. Improves lipid profiles and reduces inflammatory markers associated with lipodystrophy.
Common Dosages
subcutaneous
2mg
Daily · 3-6 months
Benefits
Reduces visceral fat
Improves body composition
Better lipid profiles
FDA-approved indication
Preserves lean mass
Side Effects
Injection site reactions
Joint pain
Muscle aches
Peripheral edema
Hyperglycemia risk
Key Research
Tesamorelin in HIV lipodystrophy
FDA approval based on significant visceral adipose tissue reduction
Regulatory Status
FDA-approved (Egrifta) specifically for HIV-associated lipodystrophy. Prescription required.
Contraindications
- ⚠Active malignancy
- ⚠Diabetic retinopathy
- ⚠Pregnancy/breastfeeding
For GLP-1 users with visceral fat concerns, tesamorelin offers a clinically-validated option alongside SeraVia formulations.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.